Epitan resumes sustained release trial
Tuesday, 06 July, 2004
Melbourne-based EpiTan (ASX:EPT) has resumed its trial of the sustained release implant for tanning drug Melanotan.
The trial is being conducted at Queensland's Clive Berghofer Cancer Research Centre with a new significantly smaller solid injectable. It will be used to determine the optimal dose for the final commercial formulation of Melanotan.
Epitan executive chairman Dr Wayne Millen said the new implant was able to be injected with a 16 gauge needle.
Personalised melanoma vaccine cuts risk of recurrence
Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...
Research project to produce fish-free omega-3
SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...
Biodegradable smart patch can detect and treat blood clots
Researchers have developed a biodegradable smart patch that detects pressure changes and releases...
